| タイトル | Title | Tonsillectomy as an effective treatment for arthralgia of SAPHO syndrome |
|----------|-------|---------------------------------------------------------------------|
| 著者 | Author(s) | Horiguchi, Sena / Fujita, Takeshi / Kinoshita, Koji / Doi, Katsumi |
| 掲載誌・巻号・ページ | Citation | Journal of Surgical Case Reports, 2020(9): rjaa288 |
| 刊行日 | Issue date | 2020-09 |
| 資源タイプ | Resource Type | Journal Article / 学術雑誌論文 |
| 版区分 | Resource Version | publisher |
| 権利 | Rights | © The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| DOI | | 10.1093/jscr/rjaa288 |
| JaLDOI | | |
| URL | | http://www.lib.kobe-u.ac.jp/handle_kernel/90007725 |
**CASE REPORT**

**Tonsillectomy as an effective treatment for arthralgia of SAPHO syndrome**

Sena Horiguchi¹, Takeshi Fujita²*, Koji Kinoshita³, and Katsumi Doi¹

¹Department of Otolaryngology, Kindai University Faculty of Medicine, Osaka, Japan, ²Department of Otorhinolaryngology Head and Neck Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan and ³Department of Hematology and Reumatology, Kindai University Faculty of Medicine, Osaka, Japan

*Correspondence address. Department of Otorhinolaryngology Head and Neck Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, Japan. Tel: +81-78-382-6024; Fax: +81-78-382-6039; E-mail: fujitake@med.kobe-u.ac.jp

**Abstract**

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome has been proposed to describe a clinicoradiological entity manifesting in the joints, skin and bones. We describe a patient with SAPHO syndrome for whom bilateral tonsillectomy was effective for the treatment of arthralgia, which was quantified using multiple pain scales.

**INTRODUCTION**

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome was proposed in 1987 to describe a clinicoradiological entity manifesting in the joints, skin and bones [1]. SAPHO syndrome is characterized by (i) hyperostosis or chronic recurrent multifocal osteomyelitis or (ii) other osteoarticular symptoms associated with dermatologic conditions, such as acne or palmoplantar pustulosis (PPP).

There are several treatment options for SAPHO syndrome, but due to the rarity of the syndrome, official therapeutic algorithms do not exist. Non-steroidal anti-inflammatory drugs are commonly administered as first-line treatment for pain relief or during the diagnostic phase, but in most cases, they are insufficient. Second-line agents include bisphosphonates, steroids and disease-modifying anti-rheumatic drugs such as methotrexate, but a significant percentage of patients fail to achieve remission.

Recently, tumor necrosis factor (TNF-α) has been shown to play a role in osteitis, which may support biologics targeting TNF-α as favorable for the treatment of SAPHO syndrome. However, the occurrence of osteoarticular or skin disease worsening or showing a lack of response to anti-TNF-α drugs has been reported, and among responders, many achieve only partial control of the disease [2–4].

Pustulotic arthro-osteitis (PAO) is a joint comorbidity of PPP, most often affecting the clavicles, sternum and sternoclavicular joints. PAO is regarded as the same entity as SAPHO syndrome [5]. Recently, tonsillectomy has been reported to be extremely effective for PPP and PAO [6].

We describe a patient with SAPHO syndrome for whom bilateral tonsillectomy was effective for the treatment of arthralgia, which was quantified using multiple pain scales, including the visual analog scale (VAS), revised version of the short-form McGill Pain Questionnaire (SF-MPQ-2) and pain disability assessment scale (PDAS).

**MATERIALS AND METHODS (PAIN SCALES)**

**Visual analog scale (VAS)**

The VAS is a unidimensional measure of pain intensity, which has been widely used in diverse populations [7]. For pain intensity, the scale is anchored by “no pain” (score of 0) and “pain as bad as it could be” or “worst imaginable pain” (score of 100).
Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2)
The SF-MPQ-2 assesses the major symptoms of both neuropathic and nonneuropathic pain [8]. The SF-MPQ-2 includes 22 pain descriptors with four subscales: one affective and three sensory (continuous pain, intermittent pain, and predominantly neuropathic pain). All pain descriptors are rated on a 0-to-10 (none to worst possible pain) numerical rating scale according to the severity of pain perceived or experience.

Pain disability assessment scale (PDAS)
The PDAS assesses the degree to which chronic pain interferes with various daily activities [9]. It includes 20 items reflecting pain interference in a broad range of daily activities, and respondents indicate the extent to which pain interferes with each activity on a Likert scale ranging from 0 (“pain does not interfere with this activity”) to 4 (“pain interferes completely with this activity”). Scores for the total PDAS can range from 0 to 60, with higher scores indicating higher levels of pain interference.

CASE REPORT

A 75-year-old woman presented with arthralgia in both wrists, shoulders, upper limbs and ankles and complained of difficulties in walking and engaging in housework. She was diagnosed with SAPHO syndrome based on the dermatological manifestations (Fig. 1A) and thickened sternoclavicular joints (Fig. 2). Her symptoms did not respond to celecoxib, methotrexate or adalimumab, an anti-TNF-α drug. After bilateral tonsillectomy, her arthralgia and skin symptoms dramatically improved. Prior to tonsillectomy, the VAS, SF-MPQ-2 and PDAS scores were 30, 37 and 28, respectively. Three months after tonsillectomy, the methotrexate dose was reduced, and the patient showed significant improvements in her skin symptoms (Fig. 1B). The 3-month postoperative VAS, SF-MPQ-2 and PDAS scores were 20, 7 and 19, respectively. Six months after tonsillectomy, the patient no longer needed celecoxib. The VAS, SF-MPQ-2 and PDAS scores were 10, 4 and 24, respectively. Twelve months after tonsillectomy, the VAS, SF-MPQ-2 and PDAS scores were 5, 5 and 12, respectively. She could walk without the help of a stick 1 year after tonsillectomy (Fig. 3).
DISCUSSION

We encountered a patient with SAPHO syndrome for whom bilateral tonsillectomy was effective for the treatment of arthralgia. After tonsillectomy, the patient could receive a lower dose of methotrexate and discontinue celecoxib treatment. The results of quantitative pain scales showed improvements in the patient’s pain and quality of life.

Although the pathogenesis of SAPHO remains unclear, it has been hypothesized that SAPHO syndrome represents an autoimmune and inflammatory process triggered by the breakdown of immune tolerance to resident bacteria in the tonsils [10]. It has been speculated that activated tonsillar T cells are increased by a hyperimmune response against α-streptococci (i.e. tonsil indigenous bacteria). In the tonsils of patients with PPP, such a novel immune response leads to the activation of T cells through the abnormal expression of secondary stimulation molecules, such as cytotoxic T-lymphocyte-associated protein-4, inducible co-stimulator and Smad7. These tonsillar T cells, with enhanced expression of lymphocyte antigen, CCR6 and β1-integrin–vascular cell adhesion protein-1 binding, may migrate to PPP skin lesions or affected joints and then produce sterile pustules and joint pain [6, 10]. Therefore, tonsillectomy is considered to be effective for PPP and PAO, which are related to SAPHO syndrome.

Here, we present the high efficacy of tonsillectomy in improving skin lesions and arthralgia based on multiple quantitative pain scales. Clinicians should at least present tonsillectomy as a treatment option for patients with SAPHO who do not show improvements with conventional treatment.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING

None.

REFERENCES

1. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-ostitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal Osteoartic 1987;54:187–96.
2. Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum 2012;42:254–65.
3. Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR. SAPHO syndrome: current developments and approaches to clinical treatment. Curr Rheumatol Rep 2016;18:35.
4. Daoussis D, Konstantopoulou G, Kraniotis P, Sakkas L, Liossis SN. Biologics in SAPHO syndrome: a systematic review. Semin Arthritis Rheum 2019;48:618–25.
5. Yamamoto T. Pustulotic arthro-osteitis associated with palmar plantar pustulosis. J Dermatol 2013;40:857–63.
6. Takahara M, Hirata Y, Nagato T, Kishibe K, Katada A, Hayashi T, et al. Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthritides: a retrospective subjective and objective quantitative analysis of 138 patients. J Dermatol 2018;45:812–23.
7. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MFQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res 2011;63:S240–52.
8. Dworkin RH, Turk DC, Trudeau JJ, Benson C, Biondi DM, Katz NF, et al. Validation of the short-form McGill pain questionnaire (SF-MPQ) and chronic pain grade scale (CPGS) in acute low back pain. J Pain 2015;16:357–66.
9. Yamashiro K, Arimura T, Iwaki R, Jensen MP, Kubo C, Hosoi M. A multidimensional measure of pain interference: reliability and validity of the pain disability assessment scale. Clin J Pain 2011;27:338–43.
10. Harabuchi Y, Takahara M. Pathogenic role of palatine tonsils in palmoplantar pustulosis: a review. J Dermatol 2019;46:931–9.